Articles By Anuja Singh
Could Johnson & Johnson’s 99.7% Acute Success in VARIPURE Substudy Redefine the Global Pulsed…
Key Highlights Breakthrough Clinical Data from ESC 2025Johnson & Johnson MedTech unveiled results from the VARIPURE substudy of…
By
Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for…
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2…
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s $27B Manufacturing Expansion Reshape the Future…
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency…
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Could Johnson & Johnson’s 99.7% Acute Success in VARIPURE Substudy Redefine the Global Pulsed…
Key Highlights Breakthrough Clinical Data from ESC 2025Johnson & Johnson MedTech unveiled results from the VARIPURE substudy of…
Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for…
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2…
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s $27B Manufacturing Expansion Reshape the Future…
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency…
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…